Floatz Rating
B60/100
Confidence
Indicative
Sponsor
University of Michigan Rogel Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05956041CT.gov Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | — | Recruiting | — | — | — |
NCT04541017CT.gov Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mycosis Fungoides And Variants
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mogamulizumab (this asset) | University of Michigan Rogel Cancer Center | P2 | B · 60 |
| Fludarabine | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | BB |
| Romidepsin | Northwestern University | P2 | BB |
| Pembrolizumab | University of Michigan Rogel Cancer Center | P2 | BB |
| Tacrolimus | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | B |
| Lenalidomide | Northwestern University | P2 | B |
| Lacutamab | Innate Pharma | P2 | B |
| Interferon Gamma-1B | National Cancer Institute (NCI) | P2 | B |
| VITPSO | European Organisation for Research and Treatment of Cancer - EORTC | P2 | CCC |
+20 more in the Mycosis Fungoides And Variants cohort
Other indications for Mogamulizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 71 |
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BB · 71 |
| Mycosis Fungoides | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mogamulizumab in Mycosis Fungoides And Variants. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mogamulizumab-mycosis-fungoides-and-variants
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →